

RESEARCH ARTICLE

Open Access

# Genome instability in blood cells of a *BRCA1*+ breast cancer family

Fengxia Xiao<sup>1†</sup>, Yeong C Kim<sup>1†</sup>, Carrie Snyder<sup>2</sup>, Hongxiu Wen<sup>1</sup>, Pei Xian Chen<sup>3</sup>, Jiangtao Luo<sup>4</sup>, Dina Becirovic<sup>2</sup>, Bradley Downs<sup>1</sup>, Kenneth H Cowan<sup>5</sup>, Henry Lynch<sup>2\*</sup> and San Ming Wang<sup>1\*</sup>

## Abstract

**Background:** *BRCA1* plays an essential role in maintaining genome stability. Inherited *BRCA1* germline mutation (*BRCA1*+) is a determined genetic predisposition leading to high risk of breast cancer. While *BRCA1*+ induces breast cancer by causing genome instability, most of the knowledge is known about somatic genome instability in breast cancer cells but not germline genome instability.

**Methods:** Using the exome-sequencing method, we analyzed the genomes of blood cells in a typical *BRCA1*+ breast cancer family with an exon 13-duplicated founder mutation, including six breast cancer-affected and two breast cancer unaffected members.

**Results:** We identified 23 deleterious mutations in the breast cancer-affected family members, which are absent in the unaffected members. Multiple mutations damaged functionally important and breast cancer-related genes, including transcriptional factor *BPTF* and *FOXP1*, ubiquitin ligase *CUL4B*, phosphorylase kinase *PHKG2*, and nuclear receptor activator *SRA1*. Analysis of the mutations between the mothers and daughters shows that most mutations were germline mutation inherited from the ancestor(s) while only a few were somatic mutation generated *de novo*.

**Conclusion:** Our study indicates that *BRCA1*+ can cause genome instability with both germline and somatic mutations in non-breast cells.

**Keywords:** *BRCA1*+, Familial breast cancer, Exome sequencing, Bioinformatics, Germline mutation, Genome instability

## Background

*BRCA1* maintains genome stability through repairing double-strand DNA damage and other mechanisms [1]. The *BRCA1* germline mutation (*BRCA1*+) is a well-known genetic predisposition for inherited breast cancer [2-4]. Women who inherited *BRCA1*+ have a 60-80% risk of developing breast cancer by the age of 70 [5]. It is believed that *BRCA1*+ leads to breast cancer by causing genome instability [6,7]. Indeed, many efforts have been made to determine the nature of *BRCA1*+ induced genome instability. Cytogenetic studies in *BRCA1*+ familial breast cancer showed the losses of 2q, 4p, 4q, 5q, and 12q [8]; analysis of a breast cancer-derived cell line HCC1937 showed aneuploidy, loss of p53 and PTEN, and loss of

heterozygosity (LOH) at multiple loci [9]; analysis in *BRCA1*+ basal-like breast cancer identified the losses of the regions containing *RB1*, *INPP4B*, *RAD17*, *RAD50*, and *RAP80* [10], and large-scale chromosomal breakage, copy number loss and LOH [11,12]. Of the three distinct classes of “simple”, “amplifier” and “complex” DNA copy-number alterations defined for breast cancer, *BRCA1*+ breast cancer fits within the “complex” class [13]. Conditional *Brcal* knockout in the mouse model results in breast tumor formation after a long latency, changes in the centrosomes, chromosomal gain and loss in specific segments orthologous to the genetic loci mutated in human breast cancer [14-16]. Data from these studies indicate that many types of genetic defects in the genome are caused by *BRCA1*+ induced genome instability.

A fundamental question remains to be answered, that is, whether *BRCA1*+ could cause germline genome instability. Most *BRCA1* mutations are founder mutations originated from the ancestor of the affected family passing

\* Correspondence: htlynch@creighton.edu; sanming.wang@unmc.edu

<sup>†</sup>Equal contributors

<sup>2</sup>Hereditary Cancer Center, Department of Preventive Medicine, Creighton University, Omaha, NE 68198, USA

<sup>1</sup>Department of Genetics, Cell Biology and Anatomy, Omaha, NE 68198, USA  
Full list of author information is available at the end of the article

through multiple generations. While *BRCA1*<sup>+</sup> is inherited at the beginning of fertilization of the *BRCA1*<sup>+</sup> carriers, breast cancer will only develop in the reproductive age. Between fertilization and reproductive age, are there any genetic changes in *BRCA1*<sup>+</sup> carrier genome besides the cancer-targeted breast cell genome, considering the essential roles of *BRCA1* in maintaining genome stability? Nearly all genome instability studies in human breast cancer have been focused on breast cancer tissue where germline changes are considered as normal genome variations and disregarded. Therefore, the information derived from previous studies reflects mainly the somatic genome instability in breast cancer cells.

We hypothesize that the loss of *BRCA1* function could cause genome instability in non-breast cancer cells. In this study, we used exome sequencing method to analyze the entire coding genes in the genomes of blood cells in a typical *BRCA1*<sup>+</sup> breast cancer family. Our study identified multiple recurrent germline and somatic mutations in the genomes of blood cells, highlighting that *BRCA1*<sup>+</sup> can cause genome instability in both breast cancer cells and non-breast cancer cells.

## Methods

### The family used for the study


The breast cancer family used in this study contains a heterozygous founder mutation, a 6 kb frameshift duplication comprising exon 13 of *BRCA1* (ins 6 kb exon13-ter1460) that originated from northern British ancestors [17,18]. This mutation is regarded as one of the frequent

founder mutations for *BRCA1* mutation testing. Eight family members across two generations were selected for exome sequencing analysis. Of those, six females were diagnosed with breast cancer at the age of 62 (#1), 53 (#2), 35 (#4), 35 (#5), 36 (#6), and 35 years old (#7), and each had inherited the founder mutation. Two members were unaffected at the age of 65 (#3, female) and 45 (#8, male), neither inherited the mutation. #9 and #10 (fathers) were used to remove the variants transmitted to their daughters #5, #6 and #7, accordingly (Figure 1). The use of the samples for the study was approved by the Institutional Review Boards of Creighton University and University of Nebraska Medical Center. All subjects signed the consent form to participate in cancer genetic study and to publish the details.

### Exome sequencing, mapping, variant calling and validation

Genomic DNA from blood cells of the selected individuals was used for this study. Exome library preparation, capture, and sequencing were performed following the Illumina exome sequencing procedures. NimbleGen SeqCap EZ human exome V2.0 kit was used for exome capture. Paired-end sequences (2x100) were collected in the Illumina HiSeq2000 sequencer. The exome data were deposited in NCBI (Accession number SRR949927).

The exome sequences were mapped to the human genome reference sequence hg19 by Bowtie2 using the default parameters in paired mode [19]. The resulting SAM files were converted to BAM files and the duplicates were



removed using Picard (<http://picard.sourceforge.net>). The mapped reads were locally realigned using GATK RealignerTargetCreator. The base quality scores were recalibrated with BaseRecalibrator using dbSNP137 in the GATK resource bundles for hg19.

VarScan 2 [20] and GATK [21] were used for variant calling following the instructions. For VarScan 2, pileup data were generated from BAM files using Samtools [22] mpileup command (with  $-B$  parameter to disable BAQ computation), and the default parameters were used with the minimum read depth at 10, minimum base quality at 30; for GATK, UnifiedGenotyper was used for variant calling. BAM files were used for variant calling with GATK v4, release 2.0 with default parameter settings, including  $stand\_call\_conf = 30$  and  $stand\_emit\_conf = 30$ , the minimum base quality score increased from 17 to 30 using dbSNP137. The variants called by VarScan 2 and GATK were annotated with ANNOVAR using the software provided databases of RefSeq, dbSNP137, 1000 Genomes [23] and ESP6500 from NHLBI Exome Sequencing Project (NHLBI GO Exome Sequencing Project, <http://evs.gs.washington.edu/EVS/>). The called variants were divided into known variants and novel variants. The known variants were further classified, based on their minor allele frequency (MAF) distribution in ESP6500 or 1000 Genome ( $\leq 0.001$ , and  $> 0.001$ ). Those with  $MAF > 0.001$  were removed as common normal variants. Those with  $MAF \leq 0.001$  and novel variants were further classified into synonymous, nonsynonymous, splicing change, stop gain, and stop loss. For the nonsynonymous variants, PolyPhen-2 [24] and SIFT [25] programs were used to identify those with predicted deleterious effects as defined by PolyPhen-2 score [Probably damaging, 0.909-1, Possibly damaging 0.447 - 0.908, Benign 0-0.446 (HumVar score)], and SIFT score covered by ANNOVAR LJB2 (Damaging  $< 0.05$ , Tolerant  $\geq 0.05$ ) [26]. The final variants include the novel variants and the rare variants ( $MAF \leq 0.001$ ) with deleterious effect, splicing alteration, and stop gain/loss. The fragile sites used for the analysis were based on the reference [27].

#### Validation

Sanger sequencing was used to validate the variants called by mapping analysis. Sense and antisense primers were designed for each candidate by Primer3 (<http://frodo.wi.mit.edu/primer3/>). PCR was performed with the same DNA used in exome sequencing (20 ng/reaction), sense and antisense primers (10 pmol), and Taq polymerase (1.25 unit, Promega) at the conditions of denaturing at 95°C 7 minutes, 38 cycles at 95°C 30 seconds, 56°C 30 seconds, 72°C 30 seconds, final extension at 72°C 7 minutes. The amplified DNA products were subject to Big-Dye sequencing reactions. Sequences were collected in a ABI3730 sequencer, and examined by using

CLC Genomics Workbench 6.5 program (CLCbio, Cambridge, Massachusetts, USA) to validate the called variants.

## Results

### Exome sequencing and variant calling

We collected paired-end (2x100) exome sequences at 119x coverage on average for each member. We used the following steps for sequence mapping and variant call. 1) Sequences were processed and variants were called by both VarScan 2 and GATK; 2) The variants shared between the affected members and the unaffected members were removed; 3) Nonsynonymous variants were identified; 4) Deleterious variants leading to loss-of-function of the affected genes were predicted by either PolyPhen-2 [24] or SIFT [25] or both programs. 5) The variants shared between the father (#9, #10) and their daughters (#5, #6, #7) were removed upon Sanger sequencing validation; 6) All the remaining variants were validated by Sanger sequencing to confirm that each variant is a real germline mutation present only in the breast cancer-affected members.

Through these processes, we identified 23 germline mutations in breast cancer-affected members in this family, of which 21 are novel mutations and 2 are rare mutations (rs143160739, rs370052455) with minor allele frequency (MAF)  $< 0.001$  (Table 1). The total frequency of the 23 mutations is 54, including 12 (52%) mutations present between 2 to 6 members, and 11 (48%) mutations present only in a single individual. On average, 9.2 mutations (54/6) are present in each breast cancer-affected member.

### Distribution of the mutations in the family

Of the 23 mutations, 12 were shared in at least two of the three *BRCA1+* breast cancer-affected sisters (#1, #2, #4), 2 were present only in sister #2 (Table 2A). We compared the variants between mother and daughter pairs. Pair 1 includes mother (#2) and two daughters (#5, #6), all are *BRCA1+* and affected with breast cancer at 53, 36 and 36 years old respectively; Pair 2 includes mother (#4) and

**Table 1 Exome data and variant calls**

Case	Total bases	Coverage	Variant called
1	5,333,230,980	133	46,317
2	3,715,176,060	93	43,510
3	8,558,235,540	213	50,533
4	5,621,290,920	140	47,064
5	3,915,557,820	98	45,531
6	3,209,882,580	80	40,598
7	3,605,428,440	90	40,211
8	4,143,350,070	103	43,996
Average	4,762,769,051	119	44,720

**Table 2 Germline mutations identified in the family**

Gene	Position	Base change	AA change	Type	SIFT		PolyPhen 2		Frequency
					Score	Prediction	Score	Prediction	
<i>SRA1</i>	chr5:139936828	c.C91T	p.P31S	SNV	0.00	D	1.00	D	6
<i>PHKG2*</i>	chr16:30767746	c.C706T	p.R236W	SNV	0.00	D	1.00	D	5
<i>ZNF24</i>	chr18:32919897	c.T464G	p.M155R	SNV	0.02	D	0.00	B	4
<i>TMPRSS7</i>	chr3:111797705	c.G1963A	p.G655S	SNV	0.00	D	1.00	D	4
<i>ABLIM2</i>	chr4:8055946	c.G791A	p.R264Q	SNV	0.05	D	1.00	D	3
<i>FOXP1</i>	chr3:71247489	c.C44T	p.A15V	SNV	0.34	T	0.98	D	3
<i>GSTK1</i>	chr7:142964824	c.G703A	p.G235R	SNV	0.02	D	1.00	D	3
<i>LACRT</i>	chr12:55028594	c.C32T	p.A11V	SNV	0.00	D	0.99	D	3
<i>PAMR1</i>	chr11:35456266	c.G1420A	p.G474R	SNV	0.00	D	1.00	D	3
<i>TTN</i>	chr2:179400887	c.G73392A	p.W24464X	Stop gain	NA	NA	NA	NA	3
<i>UEVLD</i>	chr11:18553971	c.G1312T	p.V438L	SNV	0.37	T	0.96	D	2
<i>ITGA1</i>	chr5:52240783	c.C3296G	p.S1099C	SNV	0.01	D	1.00	D	2
<i>BPTF</i>	chr17:65850386	c.A944C	p.N315T	SNV	0.00	D	1.00	D	1
<i>CACNB3</i>	chr12:49220218	c.G688A	p.A230T	SNV	0.01	D	1.00	D	1
<i>CUL4B</i>	chrX:119680410	c.A838T	p.R280X	Stop gain	NA	NA	NA	NA	1
<i>SEMA3C</i>	chr7:80374250	c.G2216A	p.R739Q	SNV	0.01	D	0.99	D	1
<i>TBC1D22B</i>	chr6:37280778	c.G1067A	p.S356N	SNV	0.03	D	0.39	B	1
<i>CHCHD1</i>	chr10:75541868	c.G35T	p.R12L	SNV	0.01	D	0.99	D	1
<i>KCTD8*</i>	chr4:44177010	c.C1219T	p.R407C	SNV	0.00	D	1.00	D	1
<i>CLCN4</i>	chrX:10176455	c.G1214A	p.C405Y	SNV	0.00	D	0.98	D	1
<i>LAT</i>	chr16:29000901	c.G634T	p.A212S	SNV	0.02	D	1.00	D	1
<i>ZNF304</i>	chr19:57868409	c.A1172T	p.Y391F	SNV	0.16	T	1.00	D	1
<i>ZNF674</i>	chrX:46359537	c.C1487A	p.P496H	SNV	0.00	D	1.00	D	1

\*Two mutations exist in ESP 6500 with MAF 0.000077, all others are novel mutations only detected in this family.  
D: probably damaging; P: possibly damaging; B: benign; T: tolerant.

daughter (#7), both are *BRCA1+* and were affected with breast cancer at 35 years old. Because the variants shared between the father and the daughter(s) were eliminated, each mutation is firmly determined as either germline mutation inherited from the mother, or somatic mutation generated *de novo* in the daughter(s). Of the 23 mutations, 15 were germline mutations between the mother and the daughter(s) (9 in Pair 1, and 6 in Pair 2); 9 were *de novo* somatic mutation only in the daughter (#5). There was no *de novo* somatic mutation in the daughter (#6) in Pair 1 or the daughter (#7) in Pair 2 (Table 2B).

#### Chromosomal distribution and ratio of transition/transversion of the mutations

The 23 mutations are enriched in several chromosomes, such as chromosome 3 (*TMPRSS7*, *FOXP1*), chromosome 16 (*LAT*, *PHKG2*) and chromosome X (*CLCN4*, *CUL4B*, *ZNF674*). Except the mutations in *ZNF304* and *ZNF674*, no mutations are located in the repetitive sequences of SINE, LINE, LTR, simple or satellite sequences. Fifteen mutations are located in the regions with known

structural variations and 5 mutations in the chromosomal fragile sites of 4A, 11E, 2G, 11C, and 18A (Table 3). For the 23 mutations, the ratio of transition/transversion (Ti/Tv) is 1.6. However, the ratio increased to 3.0 (9/3) for the common mutations. In contrast, the ratio decreased to 0.8 (5/6) for the mutations present only in single individual. The ratio between common mutations and individual mutations is statistically different by Fisher exact test ( $p = 0.009$ , Table 4).

#### Functional categories of the mutated genes

Multiple mutations have deleterious effects on functional importance and breast cancer-related genes (Table 5, Additional file 1: Table S1). Followings are examples of the mutation-affected genes:

*BPTF* is a bromodomain PHD finger transcription factor, involved in transcriptional regulation and chromatin remodeling [28]. Copy number changes in *BPTF* are present in many types of cancer [29].

*CUL4B* is an E3 ubiquitin ligase catalysing polyubiquitination for protein degradation [30].

**Table 3 Mutation distribution in the family**

Gene	Position	Base change	AA change	Sister #1 Cancer	Sister #2 Cancer	Sister #4 Cancer	Sister #3 Unaffected
A. Mutation distribution in the three breast cancer-affected sisters							
<i>PHKG2</i>	chr16:30767746	c.C706T	p.R236W	+	+	+	-
<i>GSTK1</i>	chr7:142964824	c.G703A	p.G235R	+	+	-	-
<i>ITGA1</i>	chr5:52240783	c.C3296G	p.S1099C	+	+	-	-
<i>PAMR1</i>	chr11:35456266	c.G1420A	p.G474R	+	+	-	-
<i>TMPRSS7</i>	chr3:111797705	c.G1963A	p.G655S	+	+	-	-
<i>UEVLD</i>	chr11:18553971	c.G1312T	p.V438L	+	+	-	-
<i>LACRT</i>	chr12:55028594	c.C32T	p.A11V	+	-	+	-
<i>SRA1</i>	chr5:139936828	c.C91T	p.P31S	+	-	+	-
<i>ZNF24</i>	chr18:32919897	c.T464G	p.M155R	+	-	+	-
<i>ABLIM2</i>	chr4:8055946	c.G791A	p.R264Q	-	+	+	-
<i>FOXP1</i>	chr3:71247489	c.C44T	p.A15V	-	+	+	-
<i>TTN</i>	chr2:179400887	c.G73392A	p.W24464X	-	+	+	-
<i>CACNB3</i>	chr12:49220218	c.G688A	p.A230T	-	+	-	-
<i>CHCHD1</i>	chr10:75541868	c.G35T	p.R12L	-	+	-	-
B. Mutation distribution between generations							
Pair 1				Father #9	Mother #2	Daughter #5	Daughter #6
<i>RAB3C</i>	chr5:58147140	c.G646A	p.E216K	-	+	+	+
<i>SRA1</i>	chr5:139936828	c.C91T	p.P31S	-	+	+	+
<i>TMPRSS7</i>	chr3:111797705	c.G1963A	p.G655S	-	+	+	+
<i>ZNF24</i>	chr18:32919897	c.T464G	p.M155R	-	+	+	+
<i>LACRT</i>	chr12:55028594	c.C32T	p.A11V	-	+	+	-
<i>PAMR1</i>	chr11:35456266	c.G1420A	p.G474R	-	+	+	-
<i>GSTK1</i>	chr7:142964824	c.G703A	p.G235R	-	+	-	+
<i>PHKG2</i>	chr16:30767746	c.C706T	p.R236W	-	+	-	+
<i>UEVLD</i>	chr11:18553971	c.G1312T	p.V438L	-	+	-	+
<i>ITGA1</i>	chr5:52240783	c.C3296G	p.S1099C	-	+	-	-
<i>BPTF</i>	chr17:65850386	c.A944C	p.N315T	-	-	+	-
<i>TBC1D22B</i>	chr6:37280778	c.G1067A	p.S356N	-	-	+	-
<i>SEMA3C</i>	chr7:80374250	c.G2216A	p.R739Q	-	-	+	-
<i>CUL4B</i>	chrX:119680410	c.A838T	p.R280X	-	-	+	-
<i>CLCN4</i>	chrX:10176455	c.G1214A	p.C405Y	-	-	+	-
<i>LAT</i>	chr16:29000901	c.G634T	p.A212S	-	-	+	-
<i>ZNF304</i>	chr19:57868409	c.A1172T	p.Y391F	-	-	+	-
<i>ZNF674</i>	chrX:46359537	c.C1487A	p.P496H	-	-	+	-
<i>KCTD8</i>	chr4:44177010	c.C1219T	p.R407C	-	-	+	-
Pair 2				Father #10	Mother #4	Daughter #7	Son #8
<i>SRA1</i>	chr5:139936828	c.C91T	p.P31S	-	+	+	+
<i>PHKG2</i>	chr16:30767746	c.C706T	p.R236W	-	+	+	-
<i>CASQ1</i>	chr1:160165804	c.G769A	p.E257K	-	+	+	-
<i>ABLIM2</i>	chr4:8055946	c.G791A	p.R264Q	-	+	+	-
<i>TTN</i>	chr2:179400887	c.G73392A	p.W24464X	-	+	+	-
<i>FOXP1</i>	chr3:71247489	c.C44T	p.A15V	-	+	+	-

**Table 4 Genomic features of the mutations**

**A. Genome distribution of the mutations**

Gene	Position	Repetitive sequence	Structural variation	Fragile site		
<i>BPTF</i>	chr17:65850386	-	+	-	-	-
<i>CACNB3</i>	chr12:49220218	-	+	-	-	-
<i>CHCHD1</i>	chr10:75541868	-	+	-	-	-
<i>FOXP1</i>	chr3:71247489	-	+	-	-	-
<i>GSTK1</i>	chr7:142964824	-	+	-	-	-
<i>ITGA1</i>	chr5:52240783	-	+	-	-	-
<i>LACRT</i>	chr12:55028594	-	+	-	-	-
<i>PHKG2</i>	chr16:30767746	-	+	-	-	-
<i>SRA1</i>	chr5:139936828	-	+	-	-	-
<i>CLCN4</i>	chrX:10176455	-	+	-	-	-
<i>LAT</i>	chr16:29000901	-	+	-	-	-
<i>KCTD8</i>	chr4:44177010	-	+	-	-	-
<i>ABLIM2</i>	chr4:8055946	-	+	4A	5149099	8732840
<i>PAMR1</i>	chr11:35456266	-	+	11E	31043424	36443424
<i>TTN</i>	chr2:179400887	-	+	2G	169791754	182991755
<i>UEVLD</i>	chr11:1853971	-	-	11C	16143424	21643424
<i>ZNF24</i>	chr18:32919897	-	-	18A	32746002	37246002
<i>CUL4B</i>	chrX:119680410	-	-	-	-	-
<i>SEMA3C</i>	chr7:80374250	-	-	-	-	-
<i>TBC1D22B</i>	chr6:37280778	-	-	-	-	-
<i>TMPRSS7</i>	chr3:111797705	-	-	-	-	-
<i>ZNF304</i>	chr19:57868409	+	-	-	-	-
<i>ZNF674</i>	chrX:46359537	+	-	-	-	-

**B. Transition/ transversion of the mutations**

Wild type	Mutation	Wild type	Mutation
Common mutations (> = 2)			
C	T	T	G
C	T	G	T
C	T	C	G
C	T		
G	A		
G	A		
G	A		
G	A		
G	A		
Individual mutations			
C	T	A	T
G	A	A	T
G	A	A	C
G	A	G	T
G	A	G	T
		C	A

**Table 4 Genomic features of the mutations (Continued)**

C. Transition/Transversion ratio			
Class	Transition	Transversion	Ratio
Total mutation	14	9	1.6
Common	9	3	3
Individual	5	6	0.8

FOXP1 is a member of the forkhead box (FOX) transcription factor family, involving in regulation of tissue- and cell type-specific gene expression. Its expression is under the regulation of estrogen and it is known to play a role in breast cancer cell proliferation [31].

GSTK1 (glutathione S-transferase kappa 1) is involved in cellular detoxification [32].

LACRT (lacritin) is highly expressed in lacrimal glands. Copy number amplification of LACRT was observed in breast cancer [33].

PHKG2 is a phosphorylase kinase. It is involved in liver glycogenesis. Mutations in this gene cause glycogen storage disease type 9C [34].

**Table 5 Function of mutation-damaged genes**

Genes	Function	Mutation type
ABLIM2	Actin binding	nonsynonymous SNV
BPTF	Transcriptional regulation	nonsynonymous SNV
CACNB3	Calcium channel	nonsynonymous SNV
CHCHD1	Nuclear protein	nonsynonymous SNV
CLCN4	Chloride channel	nonsynonymous SNV
CUL4B	Polyubiquitination	stop gain
FOXP1	Transcriptional regulation	nonsynonymous SNV
GSTK1	Cellular detoxification	nonsynonymous SNV
ITGA1	Cell-cell adhesion	nonsynonymous SNV
KCTD8	Potassium channel	nonsynonymous SNV
LACRT	Lacrimal gland development	nonsynonymous SNV
LAT	TCR - and pre-TCR-mediated signaling	nonsynonymous SNV
PAMR1	Muscle regeneration	nonsynonymous SNV
PHKG2	Phosphorylase kinase for glycogenesis	nonsynonymous SNV
SEMA3C	Developmental regulation	nonsynonymous SNV
SRA1	Nuclear and non-nuclear receptor Regulation	nonsynonymous SNV
TBC1D22B	Unknown	nonsynonymous SNV
TMPRSS7	Serine protease for peptide hydrolyzes	nonsynonymous SNV
TTN	Structural protein for chromosomes	stop gain
UEVLD	Unknown	nonsynonymous SNV
ZNF24	Transcriptional regulation	nonsynonymous SNV
ZNF304	Transcriptional regulation	nonsynonymous SNV
ZNF674	Transcriptional regulation	nonsynonymous SNV

SRA1 is a steroid receptor activator, involving in the regulation of many nuclear and non-nuclear receptors and associating with breast cancer [35]. The mutation in this gene is also present in the member (#8), who is a male not affected with breast cancer.

#### Comparison between germline mutations and somatic mutations in breast cancer

The Cancer Genome Atlas Network (TCGA) identified 56 somatically mutated genes from 510 breast cancer tissues, of which about 90% are sporadic breast cancer [36]. Comparison between the 23 mutated genes in our study and the 56 mutated genes shows no overlap between the two sets of mutation-affected genes. The closest correlation is the mutations in the FOX family, in which *FOXA1* is somatically mutated in sporadic breast cancer and *FOXP1* is germline-mutated in the *BRCA1+* family. Mutations in these two FOX genes are associated with breast cancer [37]. Absence of overlapping mutations between the *BRCA1+* genomes and sporadic breast cancer genomes suggests the different genetic basis between these two types of breast cancer. Searching the 23 mutations by gene name in the COSMIC database, which contain somatic mutation information for various types of human cancer, shows nineteen genes being present in COSMIC, however the mutations were at different position; searching by exact positions shows the presence of the same mutations for *KCTD8* and *CACNB3*. *KCTD8* is a component of potassium channel and *CACNB3* is a subunit of calcium channel. The oncological roles of these two mutated genes in familial breast cancer remain to be elucidated.

#### Discussion

Tumorigenesis requires multiple genetic defects to transform a normal cell to a tumor cell [38,39]. In familial breast cancer, germline mutations inherited from ancestors play important roles in cancer processes. *BRCA1+* is the strongest germline predisposition for familial breast cancer. While it is widely accepted that *BRCA1+* leads to breast cancer by causing genome instability, the detailed mechanism for how *BRCA1+* causes genome instability remain to be determined. Our study shows the presence of mutations in blood cells from the *BRCA1+* breast cancer family. By definition, only the mutations occurred shortly after fertilization can be germline mutation.

Although blood cells are frequently used in solid tumor genetic study to represent germline genome, the mutations detected in blood cells in fact include both true germline mutations occurred during fertilization and somatic mutations occurred after fertilization. By combining the pedigree information, however, we can clearly distinguish the two types of mutations that those shared between generations (mothers and daughters) are the germline mutation, and those only presented in single individual (#2 daughter) are *de novo* somatic mutations. The number of germline mutations is much larger than the number of *de novo* somatic mutations, this is due to the fact that germline mutations are accumulated/inherited from multiple generations whereas somatic mutations are only present in individual generation. The results indicate that *BRCA1+* can induce germline genome instability represented by the genome of blood cells.

Can the small numbers of mutations be identified by chance? For the following reasons, we consider it unlikely: in the study, we applied a multi-step mapping pipeline in order to maximally differentiate germline mutations associated with cancer from abundant normal variants, including the filtration of normal variants using public variant databases of dbSNP, 1000 genomes and exome variation databases, the use of the aged, unaffected family members to remove private variants in the family, exclusion of the contribution of father's germline mutation to the daughter in the trios, the focus only on the deleterious mutations causing non-synonymous mutations, splicing alternation and stop gain/loss, and the use of Sanger sequencing validation. It is also worth indicating that the functionally important mutations in cancer are in small numbers [40,41]. The small number of mutations identified were likely generated by *BRCA1+* directly or indirectly. Their roles could be promoting oncogenesis, or function as *BRCA1+* modifiers to amplify the oncogenic function of *BRCA1+*. Our study focuses on the deleterious mutations at single-based level. Other types of genetic changes could also be present in *BRCA1+* genome. For example, increased CNV in TP53 was shown to be present in Li-Fraumeni syndrome, a disease closely related with *BRCA1+* familial breast cancer [42].

It is well known that transition occurs at a higher rate than transversion mutations in cancer cells [40]. Indeed, we observed a higher Ti/Tv ratio (3.0) than that in the normal genome (2.1) for the common mutations, implying that the germline genome instability also follows the same trend that found in somatic genome mutation. However, the ratio of Ti/Tv mutations in the individual mutations (0.8) is lower than that in the normal genome. Possible causes could be that the individual mutations tend to be random events, with less biological significance, or that the number of those mutations is too small for the comparison.

Elimination of family-specific normal variants is a key to identify the true predispositive mutations in the cancer, as a normal human predispositive genome can have multiple genes mutated [43]. Familial-specific normal variants cannot be removed solely by referring to the population-based variation databases, as many familial-specific normal variants are not included. The unaffected family members can serve as the closest control for this purpose. While this process could remove certain real mutations shared between the unaffected and affected members (low penetrant), and certain family-specific normal variants could still remain in the affected members (not present in the unaffected members), the mutations present only in the affected members are more likely to be associated with cancer than those shared between the affected and unaffected members. Referring to functional importance of the mutation-affected genes also helps to identify true predispositive mutations. Because of the mutations we identified are present only in the cancer members, shared between multiple cancer-affected members in the disease family, and have functional relevance to cancer, they are most likely associated with breast cancer in the disease family.

## Conclusions

Our study shows the presence of genome instability in the genomes of non-breast cells in the *BRCA1+* familial breast cancer family. The presence of germline mutations provides a potential source to identify genetic targets for early intervention of tumorigenesis process in *BRCA1+* carriers long before tumor formation in breast cells, for which there are currently limited options besides preventive surgery.

## Availability of supporting data

The exome data generated by the study were deposited in NCBI (Accession number SRP028652). url: <http://www.ncbi.nlm.nih.gov/Traces/sra/?study=SRP028652>

## Additional file

**Additional file 1: Table S1.** Validation by Sanger sequencing.

## Competing interests

The authors declare that they have no competing interests.

## Authors' contributions

FX, HW, PXC, BD performed experiments, YK performed bioinformatic data analysis, CS, DB identified the subjects and prepared DNA samples, JL performed statistical analysis, KY, HL, SMW conceived the study, SMW designed the experiment and wrote the paper. All authors read and approved the final manuscript.

## Acknowledgments

The study was supported by a pilot grant from Fred & Pamela Buffett Cancer Center, University of Nebraska Medical Center (SMW), a NIH grant 1R21CA180008 (SMW), an Overseas Study Scholarship by China Scholarship



Council (FX). the Charles F. and Mary C. Heider Chair in Cancer Research (HL) and by revenue from Nebraska cigarette taxes awarded to Creighton University by the Nebraska Department of Health and Human Services (HL).

#### Author details

<sup>1</sup>Department of Genetics, Cell Biology and Anatomy, Omaha, NE 68198, USA. <sup>2</sup>Hereditary Cancer Center, Department of Preventive Medicine, Creighton University, Omaha, NE 68198, USA. <sup>3</sup>Department of Medicine, College of Medicine, Omaha, NE 68178, USA. <sup>4</sup>Department of Biostatistics, College of Public Health, Omaha, NE 68178, USA. <sup>5</sup>Fred & Pamela Buffett Cancer Center, University of Nebraska Medical Center, Omaha, NE 68178, USA.

Received: 17 January 2014 Accepted: 7 May 2014

Published: 19 May 2014

#### References

1. Welch PL, King MC: **BRCA1 and BRCA2 and the genetics of breast and ovarian cancer.** *Hum Mol Genet* 2001, **10**:705–713.
2. Hall JM, Lee MK, Newman B, Morrow JE, Anderson LA, Huey B, King MC: **Linkage of early-onset familial breast cancer to chromosome 17q21.** *Science* 1990, **250**:1684–1689.
3. Narod SA, Feunteun J, Lynch HT, Watson P, Conway T, Lynch J, Lenoir GM: **Familial breast-ovarian cancer locus on chromosome 17q12-q23.** *Lancet* 1991, **338**:82–83.
4. Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S, Liu Q, Cochran C, Bennett LM, Ding W, Bell R, Rosenthal J, Hussey C, Tran T, McClure M, Frye C, Hattier T, Phelps R, Haugen-Strano A, Katcher H, Yakumo K, Gholami Z, Shaffer D, Stone S, Bayer S, Wray C, Bogden R, Dayananth P, Ward J, Tonin P, Narod S: **A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1.** *Science* 1994, **266**:66–71.
5. U.S. Preventive Services Task Force: **Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility: recommendation statement.** *Ann Intern Med* 2005, **143**:355–361.
6. Venkitaraman AR: **Cancer susceptibility and the functions of BRCA1 and BRCA2.** *Cell* 2002, **108**:171–182.
7. Stratton MR, Rahman N: **The emerging landscape of breast cancer susceptibility.** *Nat Genet* 2008, **40**:17–22.
8. Tirkkonen M, Johannsson O, Agnarsson BA, Olsson H, Ingvarsson S, Karhu R, Tanner M, Isola J, Barkardottir RB, Borg A, Kallioniemi OP: **Distinct somatic genetic changes associated with tumor progression in carriers of BRCA1 and BRCA2 germ-line mutations.** *Cancer Res* 1997, **57**:1222–1227.
9. Tomlinson GE, Chen TT, Stastny VA, Virmani AK, Spillman MA, Tonk V, Blum JL, Schneider NR, Wistuba II, Shay JW, Minna JD, Gazdar AF: **Characterization of a breast cancer cell line derived from a germ-line BRCA1 mutation carrier.** *Cancer Res* 1998, **58**:3237–3242.
10. Weigman VJ, Chao HH, Shabalin AA, He X, Parker JS, Nordgard SH, Grushko T, Huo D, Nwachukwu C, Nobel A, Kristensen VN, Borresen-Dale AL, Olopade OI, Perou CM: **Basal-like Breast cancer DNA copy number losses identify genes involved in genomic instability, response to therapy, and patient survival.** *Breast Cancer Res Treat* 2012, **133**:865–880.
11. Popova T, Manié E, Rieunier G, Caux-Moncoutier V, Tirapo C, Dubois T, Delattre O, Sigal-Zafrani B, Bollet M, Longy M, Houdayer C, Sastre-Garau X, Vincent-Salomon A, Stoppa-Lyonnet D, Stern M: **Ploidy and large-scale genomic instability consistently identify basal-like breast carcinomas with BRCA1/2 inactivation.** *Cancer Res* 2012, **72**:5454–5462.
12. Konishi H, Mohseni M, Tamaki A, Garay JP, Croessmann S, Karnan S, Ota A, Wong HY, Konishi Y, Karakas B, Tahir K, Abukhdeir AM, Gustin JP, Cidado J, Wang GM, Cosgrove D, Cochran R, Jelovac D, Higgins MJ, Arena S, Hawkins L, Lauring J, Gross AL, Heaphy CM, Hosokawa Y, Gabrielson E, Meeker AK, Visvanathan K, Argani P, Bachman KE, Park BH: **Mutation of a single allele of the cancer susceptibility gene BRCA1 leads to genomic instability in human breast epithelial cells.** *Proc Natl Acad Sci U S A* 2011, **108**:17773–17778.
13. Kwei KA, Kung Y, Salari K, Holcomb IN, Pollack JR: **Genomic instability in breast cancer: pathogenesis and clinical implications.** *Mol Oncol* 2010, **4**:255–266.
14. Xu X, Wagner KU, Larson D, Weaver Z, Li C, Ried T, Hennighausen L, Wynshaw-Boris A, Deng CX: **Conditional mutation of Brca1 in mammary epithelial cells results in blunted ductal morphogenesis and tumour formation.** *Nat Genet* 1999, **22**:37–43.
15. Shen SX, Weaver Z, Xu X, Li C, Weinstein M, Chen L, Guan XY, Ried T, Deng CX: **A targeted disruption of the murine Brca1 gene causes gamma-irradiation hypersensitivity and genetic instability.** *Oncogene* 1998, **17**:3115–3124.
16. Brodie SG, Xu X, Qiao W, Li WM, Cao L, Deng CX: **Multiple genetic changes are associated with mammary tumorigenesis in Brca1 conditional knockout mice.** *Oncogene* 2001, **20**:7514–7523.
17. Puget N, Sinilnikova OM, Stoppa-Lyonnet D, Audouyoud C, Pagès S, Lynch HT, Goldgar D, Lenoir GM, Mazoyer S: **An Alu-mediated 6-kb duplication in the BRCA1 gene: a new founder mutation?** *Am J Hum Genet* 1999, **64**:300–302.
18. The BRCA1 Exon 13 Duplication Screening Group: **The exon 13 duplication in the BRCA1 gene is a founder mutation present in geographically diverse populations.** *Am J Hum Genet* 2000, **67**:207–212.
19. Langmead B, Salzberg SL: **Fast gapped-read alignment with Bowtie2.** *Nat Methods* 2012, **9**:357–359.
20. Koboldt DC, Zhang Q, Larson DE, Shen D, McLellan MD, Lin L, Miller CA, Mardis ER, Ding L, Wilson RK: **VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing.** *Genome Res* 2012, **22**:568–576.
21. McKenna A, Hanna M, Banks E, Sivachenko A, Cibulskis K, Kernysky A, Garimella K, Altshuler D, Gabriel S, Daly M, DePristo MA: **The genome analysis toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data.** *Genome Res* 2010, **20**:1297–1303.
22. Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N, Marth G, Abecasis G, Durbin R, 1000 Genome Project Data: **The sequence alignment/map (SAM) format and SAMtools.** *Bioinformatics* 2009, **25**:2078–2079.
23. The 1000 Genomes Project Consortium: **An integrated map of genetic variation from 1,092 human genomes.** *Nature* 2012, **491**:56–65.
24. Adzhubei IA, Schmidt S, Peshkin L, Ramensky VE, Gerasimova A, Bork P, Kondrashov AS, Sunyaev SR: **A method and server for predicting damaging missense mutations.** *Nat Methods* 2010, **7**:248–249.
25. Kumar P, Henikoff S, Ng PC: **Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm.** *Nat Protoc* 2009, **4**:1073–1081.
26. Wang K, Li M, Hakonarson H: **ANNOVAR: Functional annotation of genetic variants from next-generation sequencing data.** *Nucleic Acids Res* 2010, **38**:e164.
27. Fungtammasan A, Walsh E, Chiaromonte F, Eckert KA, Makova KD: **A genome-wide analysis of common fragile sites: what features determine chromosomal instability in the human genome?** *Genome Res* 2012, **22**:993–1005.
28. Ruthenburg AJ, Li H, Milne TA, Dewell S, McGinty RK, Yuen M, Ueberheide B, Dou Y, Muir TW, Patel DJ, Allis CD: **Recognition of a mononucleosomal histone modification pattern by BPTF via multivalent interactions.** *Cell* 2011, **145**:692–706.
29. Buganim Y, Goldstein I, Lipson D, Milyavsky M, Polak-Charcon S, Mardoukh C, Solomon H, Kalo E, Madar S, Brosh R, Perelman M, Navon R, Goldfinger N, Barshack I, Yakhini Z, Rotter V: **A novel translocation breakpoint within the BPTF gene is associated with a pre-malignant phenotype.** *PLoS One* 2010, **5**:e9657.
30. Nakagawa T, Xiong Y: **X-linked mental retardation gene CUL4B targets ubiquitylation of H3K4 methyltransferase component WDR5 and regulates neuronal gene expression.** *Mol Cell* 2011, **43**:381–391.
31. Shigekawa T, Ijichi N, Ikeda K, Horie-Inoue K, Shimizu C, Saji S, Aogi K, Tsuda H, Osaki A, Saeki T, Inoue S: **FOXP1, an estrogen-inducible transcription factor, modulates cell proliferation in breast cancer cells and 5-year recurrence-free survival of patients with tamoxifen-treated breast cancer.** *Horm Cancer* 2011, **2**:286–297.
32. Robinson A, Huttley GA, Booth HS, Board PG: **Modelling and bioinformatics studies of the human Kappa-class glutathione transferase predict a novel third glutathione transferase family with similarity to prokaryotic 2-hydroxychromene-2-carboxylate isomerases.** *Biochem J* 2004, **379**(Pt3):541–552.
33. Porter D, Weremowicz S, Chin K, Seth P, Keshaviah A, Lahti-Domenici J, Bae YK, Monitto CL, Merlos-Suarez A, Chan J, Hulette CM, Richardson A, Morton CC, Marks J, Duyao M, Hruban R, Gabrielson E, Gelman R, Polyak K: **A neural survival factor is a candidate oncogene in breast cancer.** *Proc Natl Acad Sci U S A* 2003, **100**:10931–10936.
34. Burwinkel B, Rootwelt T, Kvittingen EA, Chakraborty PK, Kilimann MW: **Severe phenotype of phosphorylase kinase-deficient liver glycogenosis with mutations in PHKG2 gene.** *Pediatr Res* 2003, **54**:834–839.
35. Chooniedass-Kothari S, Vincett D, Yan Y, Cooper C, Hamedani MK, Myal Y, Leygue E: **The protein encoded by the functional steroid receptor RNA**

- activator is a new modulator of ER alpha transcriptional activity. *FEBS Lett* 2010, **584**:1174–1180.
36. Cancer Genome Atlas Network: **Comprehensive molecular portraits of human breast tumours.** *Nature* 2012, **490**:61–70.
  37. Ijichi N, Shigekawa T, Ikeda K, Horie-Inoue K, Shimizu C, Saji S, Aogi K, Tsuda H, Osaki A, Saeki T, Inoue S, Inoue S: **Association of double-positive FOXA1 and FOXP1 immunoreactivities with favorable prognosis of tamoxifen-treated breast cancer patients.** *Horm Cancer* 2012, **3**:147–159.
  38. Hahn WC, Weinberg RA: **Rules for making human tumor cells.** *N Engl J Med* 2002, **347**:1593–1603.
  39. Rubin AF, Green P: **Mutation patterns in cancer genomes.** *Proc Natl Acad Sci U S A* 2009, **106**(51):21766–21870.
  40. Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA Jr, Kinzler KW: **Cancer genome landscapes.** *Science* 2013, **339**(6127):1546–1558.
  41. Garraway LA, Lander ES: **Lessons from the cancer genome.** *Cell* 2013, **153**(1):17–37.
  42. Shlien A, Tabori U, Marshall CR, Pienkowska M, Feuk L, Novokmet A, Nanda S, Druker H, Scherer SW, Malkin D: **Excessive genomic DNA copy number variation in the Li-Fraumeni cancer predisposition syndrome.** *Proc Natl Acad Sci U S A* 2008, **105**:11264–11269.
  43. MacArthur DG, Balasubramanian S, Frankish A, Huang N, Morris J, Walter K, Jostins L, Habegger L, Pickrell JK, Montgomery SB, Albers CA, Zhang ZD, Conrad DF, Lunter G, Zheng H, Ayub Q, DePristo MA, Banks E, Hu M, Handsaker RE, Rosenfeld JA, Fromer M, Jin M, Mu XJ, Khurana E, Ye K, Kay M, Saunders GI, Suner MM, Hunt T: **A systematic survey of loss-of-function variants in human protein-coding genes.** *Science* 2012, **335**(6070):823–828.

doi:10.1186/1471-2407-14-342

**Cite this article as:** Xiao et al.: Genome instability in blood cells of a *BRCA1+* breast cancer family. *BMC Cancer* 2014 **14**:342.

**Submit your next manuscript to BioMed Central  
and take full advantage of:**

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at  
www.biomedcentral.com/submit

